Post by
ghayes on Nov 05, 2021 3:44pm
analyst's review.
I am keeping a close eye on the RSI .. possibly a dead cat bounce coming ?
Here's the first paragraph of RJ analyst's take on the latest activity of PROF.
sorry the formatting won't copy over.
RECOMMENDATION Profound Medical (PROF-NASDAQ, SB1) reported 3Q21 results last night with a wide miss on Rev. ($2.5 mln vs. $3.1 mln RJe; $3.5 mln consensus; see our Pre-3Q21 expectations).
So, with this Q’s disappointing revenue, we have taken a moment to reflect on our view of PROF. We have always believed the right way to think about this stock is on an 18-month time horizon, certainly not quarter-to-quarter; however, while our conviction in PROF’s fundamentals remain undiminished, we do owe a mea culpa on the fact that we got the timing of our call wrong by ~1 year(explanationonpg.2). As such, we take this opportunity to adjust our revenue estimates to what we believe is a reasonable baseline that PROF should meet—if not, beat—going forward. As such, we cut our 2022 EV/Rev.-driven target price to $28, but, maintaining our focus on PROF’s exceedingly strong fundamentals, we reiterate our Strong Buy ratin
Comment by
ghayes on Nov 08, 2021 11:48am
the dead cat bounce happened...I was in at $11.31 , if it doesn't breach 13 in a day or so I will be out.. lets see if the interest is sustained. GLTA
Comment by
HomerAndCompany on Nov 09, 2021 8:32am
Is that based on your technical analysis having $13 signaling a breakout to the upside?
Comment by
ghayes on Nov 09, 2021 12:00pm
Yep and I am out today, 10% gain in a couple of days will do. 12.50. and RSI is approaching the 50% it was before the drop, It is a good product, and will certainly be back to its pre-bad-news price - but may take a few weeks to get there. just one mans opinion. GLTA. over and out.